IP Library Granted Patent US 10,869,951
Granted Patent B2
US 10,869,951 · App. 16/260,733 · Granted Dec 22, 2020

Tissue grafts modified with a cross-linking agent and method of making and using the same

Inventors: Brenda S. Morse (Marietta, GA); Somaly Sith (Marietta, GA); Randall Spencer (Marietta, GA); John Daniel (Marietta, GA)
Assignee: MiMedx Group, Inc.
A61L27/3604A61K35/50A61L27/3687A61L2430/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,869,951
App. No.
16/260,733
Granted
Dec 22, 2020
Kind
B2
Abstract

Described herein are tissue grafts derived from the placenta that possess good adhesion to biological tissues and are useful in would healing applications. In one aspect, the tissue graft includes (1) two or more layers of amnion, wherein at least one layer of amnion is cross-linked, (2) two or more layers of chorion, wherein at least one layer of amnion is cross-linked, or (3) one or more layers of amnion and chorion, wherein at least one layer of amnion and/or chorion is cross-linked. In another aspect, the grafts are composed of amnion and chorion cross-linked with one another. In a further aspect, the grafts have one or more layers sandwiched between the amnion and chorion membranes. The amnion and/or the chorion are treated with a cross-linking agent prior to the formation of the graft. The presence of the cross-linking agent present on the graft also enhances adhesion to the biological tissue of interest. Also described herein are methods for making and using the tissue grafts.

Claims (20)

1. A method for enhancing adhesion of a tissue graft to a biological tissue of a patient, said method comprising applying a tissue graft to said biological tissue of a patient, wherein said tissue graft comprises (1) two or more layers of amnion, wherein at least one layer of amnion is treated with a cross-linking agent and comprises a cross-linking group; or (2) one or more layers of amnion and chorion, wherein at least one layer of amnion and/or chorion is treated with a cross-linking agent and comprises a cross-linking group; wherein one or more of said cross-linking groups forms a covalent bond with said biological tissue, thereby enhancing adhesion of the tissue graft to the biological tissue; wherein at least one layer of amnion or chorion has not been treated with a cross-linking agent; wherein the tissue graft comprises a first surface and a second surface, where the first surface is a basement membrane and the second surface is not a basement membrane; and wherein the tissue graft is not decellularized.

2. The method of claim 1 , wherein the tissue graft comprises two or more layers of amnion, wherein at least one layer of said amnion is treated with a cross-linking agent, wherein said treated amnion comprises a cross-linking group.

3. The method of claim 1 , wherein the tissue graft comprises one or more layers of amnion and one or more layers of chorion, wherein at least one layer of said amnion and/or said chorion is treated with a cross-linking agent, and wherein said treated amnion and/or chorion comprises a cross-linking group.

4. The method of claim 1 , wherein more than one layer of amnion and/or chorion is treated with a cross-linking agent and comprises a cross-linking group, and the amnion layers and/or the chorion layers are treated with the same cross-linking agent.

5. The method of claim 1 , wherein more than one layer of amnion and/or chorion is treated with a cross-linking agent and comprises a cross-linking group, and the amnion layers and/or the chorion layers are treated with different cross-linking agents.

6. The method of claim 1 , wherein the cross-linking agent comprises a sugar, a dialdehyde, a carbodiimide, or a combination thereof.

7. The method of claim 6 , wherein the sugar comprises D-ribose, glycerose, altrose, talose, ertheose, glucose, lyxose, mannose, xylose, gulose, arabinose, idose, allose, galactose, maltose, lactose, sucrose, cellibiose, gentibiose, melibiose, turanose, trehalose, isomaltose, or any combination thereof.

8. The method of claim 1 , wherein the tissue graft includes an embossed texture or design.

9. The method of claim 1 , wherein the tissue graft comprises one or more additional membranes treated with a cross-linking agent.

10. The method of claim 9 , wherein the one or more additional membranes comprise amnion, chorion, allograft pericardium, allograft acellular dermis, amniotic membrane, Wharton's jelly, purified xenograft Type-1 collagen, biocellulose polymers or copolymers, biocompatible synthetic polymer or copolymer films, purified small intestinal submucosa, bladder acellular matrix, cadaveric fascia, or any combination thereof.

11. The method of claim 9 , wherein the one or more additional membranes comprise an amnion membrane.

12. The method of claim 1 , wherein the biological tissue comprises a wound and said tissue graft is a wound dressing.

13. The method of claim 1 , wherein the biological tissue is the spinal dura of the patient or a region near the spine, and the tissue graft is applied after a surgical procedure to prevent or reduce scar formation on or near the spine.

14. The method of claim 13 , wherein the surgical procedure comprises a posterior procedure.

15. The method of claim 14 , wherein the posterior procedure is a laminectomy, discectomy, a Posterior Lumbar Interbody Fusion, or a Transforaminal Lumbar Interbody Fusion.

16. The method of claim 13 , wherein the surgical procedure comprises an anterior procedure.

17. The method of claim 1 , wherein the tissue graft is applied to the biological tissue without the use of a suture.

18. The method of claim 1 , wherein the biological tissue is the spinal dura of the patient, and the tissue graft is applied after a dural tear.

19. The method of claim 1 , wherein the biological tissue comprises a wound and the tissue graft is applied to the wound, wherein the wound is in the cranial dura, a wound resulting from a perioplastic procedure, a frenum pull, lost patella tissue, associated with the Schneiderian membrane in the sinus cavity, or associated with the soft tissue around dental implants, wherein the tissue graft promotes healing of the wound.

20. The method of claim 1 , wherein the biological tissue comprises a wound associated with a dental surgical procedure, an orthopedic application, an ENT application, a gynecological application, an urological application, or general surgery, or wherein the biological tissue comprises an extremity having a wound, or wherein the biological tissue comprises an eye.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2024
From: HAYFIN SERVICES LLP
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 066493/0322 →
SECURITY INTEREST Recorded Jan 25, 2024
From: MIMEDX GROUP, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 066371/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2020
From: MORSE, BRENDA S.; SITH, SOMALY; SPENCER, RANDALL; DANIEL, JOHN
To: MIMEDX GROUP, INC.
Reel/Frame 054239/0811 →
PATENT SECURITY AGREEMENT Recorded Jul 2, 2020
From: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
To: HAYFIN SERVICES LLP, AS COLLATERAL AGENT
Reel/Frame 053121/0833 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 054075/0687 →
SECURITY INTEREST Recorded Jun 11, 2019
From: MIMEDX GROUP, INC.
To: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 049426/0863 →
Continuity (4)
Division 15074949 · Mar 18, 2016
Continuation 13984842
Provisional Application 61442348 · Feb 14, 2011
Related Publication 20190192736A1 · Jun 27, 2019